Novartis Phase 3 Trial for Hemoglobinuria Drug Iptacopan Met Primary Endpoint

By Pierre Bertrand

Novartis AG said Thursday that a Phase 3 trial for its drug iptacopan has met its primary endpoint of boosting hemoglobin levels.

The Swiss pharma company said the trial showed that patients treated twice daily with the drug achieved clinically meaningful hemoglobin-level increases without the need for blood transfusions at 24 weeks.

Iptacopan is a treatment for blood disease paroxysmal nocturnal hemoglobinuria, which causes the premature death of red blood cells. Patients with PNH suffer anemia, fatigue and require blood transfusions.

Write to Pierre Bertrand at [e-mail]

(END) Dow Jones Newswires

12-08-22 0157ET